ConductScience.org, home

Comparison · NCT03869385-4aeff39a

Albumin Group vs Control Group Without Albumin:: 60-day Mortality

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Albumin Group vs Control Group Without Albumin:: 60-day Mortality. Trial comparisons, record NCT03869385-4aeff39a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03869385-4aeff39a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3890.3250.456wilson
Risk in group 20.4520.3870.52wilson
Risk difference, group 1 minus group 2-0.0638-0.1560.0303newcombe hybrid score
Risk ratio, group 1 over group 20.8590.6861.08log
Odds ratio, group 1 over group 20.7690.5221.13log
Number needed to treat, for one fewer participant with the outcome on Albumin Group than on Control Group Without Albumin:15.7from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Albumin Group
Patients assigned to the Albumin group received a 60 g loading dose of human albumin 20% over 2-3 hours. Serum albumin levels were maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion.
82211OG000
Group 2Control Group Without Albumin:The control group was treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock.95210OG001

Outcome

Type
SECONDARY
Title
60-day Mortality
Description
Mortality within 60 days after randomisation
Time frame
60 days
Population
At 60 days after randomization, informed consent was not possible to be obtained within 72 hours of randomization in 14 patients, 2 patients withdrew consent, 2 patients were lost to follow-up, and the study was terminated in one patient due to investigator decision. Therefore, 60-days mortality were available in 211 vs. 210 patients in the albumin vs. control group, respectively

Source ClinicalTrials.gov

Trial

Title
Albumin Replacement Therapy in Septic Shock
NCT number
NCT03869385
Phases
PHASE3
Conditions
Septic Shock
Interventions
Albutein® 200 g/L or Plasbumin® 20
Lead sponsor
Jena University Hospital
Results first posted
2024-10-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03869385-4aeff39a